Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Production of Pravastatin Drug Substance to Resume in Sept.: Daiichi Sankyo
May 2, 2011
- Eisai's Halaven for Inoperable Breast Cancer
May 2, 2011
- Lixisenatide Reduces HbA1c in Combination with SU or SU + Metformin
May 2, 2011
- No Problem with Radioactive Contamination of Drugs: FPMAJ
May 2, 2011
- Daiichi Sankyo's Edoxaban for VTE Prevention
May 2, 2011
- Toyobo, Kyowa Medex to Comarket GENECUBE
May 2, 2011
- DSP's 200 Pharmacist Employees to Volunteer in Disaster Area
May 2, 2011
- Mochida's Lexapro for Depression
May 2, 2011
- Drugs Provided Free of Charge to Be Reimbursed in Disaster Areas
May 2, 2011
- Astellas Pharma Announces Changes in Leadership
May 2, 2011
- Japan's 1st Transdermal Patch for AD Rivastigmine: Novartis, Ono
May 2, 2011
- Lilly to Expand Japan Business via Alliances with Subsidiaries in Other Asian Countries
May 2, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
- JMA to Propose Postponing Revision of Medical, Nursing Fees
May 2, 2011
- Xyzal Ranked No. 1 in GP Market in February: RepTrack Survey
May 2, 2011
- Members of JMA Board of Trustees Disagree on Resolution to Postpone Revisions
May 2, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
May 2, 2011
- Nat'l Consensus Needed on Drugs' Cost-effectiveness Assessment: Prof. Endo
May 2, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…